ReviewSeminars in immunopathology2020
Omics for the future in asthma.
Review in Seminars in immunopathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Plasma protein signatures of adult asthma.Allergy · 2024Pooled it
- Multi‑omics insights into uveitis: From mechanisms to precision medicine (Review).International journal of molecular medicine · 2026Review
- Heterojunction-Engineered Mass Spectrometry Platform for Deciphering Serum Metabolic Fingerprints in Diagnosis of Respiratory Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Metabolomic Approaches to Lung Function in Pediatric Asthma: A Narrative Review.Children (Basel, Switzerland) · 2026Review
- The evolution of scientific knowledge in childhood asthma over time.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Current understanding and future directions in severe asthma through artificial intelligence-integrated multi-omic approaches.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Correlation between two novel visceral fat indicators and all-cause mortality among patients with asthma.BMC pulmonary medicine · 2026Article
- The transition from winter to spring has an impact on the airway metabolome profile of asthmatic horses.PloS one · 2026Article
- Article
- Gut microbiota-metabolome crosstalk in allergic diseases: mechanistic insights and translational opportunities.Frontiers in allergy · 2025Review
- Sex differences in asthma: omics evidence and future directions.Frontiers in genetics · 2025Review
- Associations of advanced lung cancer inflammation index with all-cause and respiratory disease mortality in adults with asthma: NHANES, 1999-2018.Scientific reports · 2024Article
- Implementation of multiomic mass spectrometry approaches for the evaluation of human health following environmental exposure.Molecular omics · 2024Review
- CDC167 exhibits potential as a biomarker for airway inflammation in asthma.Mammalian genome : official journal of the International Mammalian Genome Society · 2024Article
- Omics approaches in asthma research: Challenges and opportunities.Chinese medical journal pulmonary and critical care medicine · 2024Review
- Unraveling heterogeneity and treatment of asthma through integrating multi-omics data.Frontiers in allergy · 2024Review
- Asthma Phenotypes in the Era of Personalized Medicine.Journal of clinical medicine · 2023Review
- Severe Asthma and Biological Therapies: Now and the Future.Journal of clinical medicine · 2023Review
- Collision cross section measurement and prediction methods in omics.Journal of mass spectrometry : JMS · 2023Review
- Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022.Breathe (Sheffield, England) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a common, complex, multifaceted disease. It comprises multiple phenotypes, which might benefit from treatment with different types of innovative targeted therapies. Refining these phenotypes and understanding their underlying biological structure would help to apply precision medicine approaches. Using different omics methods, such as (epi)genomics, transcriptomics, proteomics, metabolomics, microbiomics, and exposomics, allowed to view and investigate asthma from diverse angles. Technological advancement led to a large increase in the application of omics studies in the asthma field. Although the use of omics technologies has reduced the gap between bench to bedside, several design and methodological challenges still need to be tackled before omics can be applied in asthma patient care. Collaborating under a centralized harmonized work frame (such as in consortia, under consistent methodologies) could help worldwide research teams to tackle these challenges. In this review, we discuss the transition of single biomarker research to multi-omics studies. In addition, we deliberate challenges such as the lack of standardization of sampling and analytical methodologies and validation of findings, which comes in between omics and personalized patient care. The future of omics in asthma is encouraging but not completely clear with some unanswered questions, which have not been adequately addressed before. Therefore, we highlight these questions and emphasize on the importance of fulfilling them.
Indexed as
Identifiers
31942640What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.